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Background: QTc prolongation and Torsade de Ppointes have been reported in patients on methadone maintenance.
Objectives: In this study, QTc was compared before and after the veteran (n = 49) was on a stable dosage of methadone for 8.72 ± 4.50 years to treat heroin dependence. Risk factors were correlated with the QTc once the veteran was on a stable dose of methadone. Differences in the clinical risk factors in subgroups of veterans with below and above mean QTc change was compared.
Patients and Methods: ECG data was obtained from a 12-lead electrocardiogram (pre-methadone and on methadone) on 49 veterans. Data and risk factors were retrospectively collected from the medical records.
Results: The mean QTc at baseline (pre-methadone) was 426 ± 34 msec and after being on methadone for an average of 8.72 ± 4.50 years was significantly higher at 450 ± 35 msec. No significant relationships were found between QTc prolongation and risk factors except for calcium. The methadone dosage was significantly higher in veterans with a QTc change above the mean change of ≥ 24 msec (88.48 ± 27.20 mg v.s 68.96 ± 19.84 mg). None of the veterans experienced cardiac arrhythmias.
Conclusions: The low complexity of medical co-morbidities may explain the lack of a significant correlation between any risk factor with the QTc except calcium and methadone dosage. The absence of TdP may be explained by the low prevalence of QTc values > 500 msec as well as the retrospective design of the study. During long-term methadone treatment, there was a slight increase in the QTc interval but we did not find evidence of increased cardiac toxicity as a reason for treatment termination.
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1. BackgroundSince the advent of methadone maintenance programs, there has been an overall increase in the life expectancy of heroin users (1). Methadone, a mu-receptor agonist, is a synthetic opiate that is commonly used in the treatment of opiate dependence (1). However, there are concerns regarding the disturbance of cardiac rhythm among in-dividuals receiving methadone maintenance treatment, e.g., Torsade de Ppointes (TdP) secondary to rate-corrected QT interval prolongation (QTc) (1-3). There are many pro-posed thresholds for determining the value at which the QTc is considered prolonged; however, international reg-ulatory guidelines suggest a sex-independent categorical threshold for QTc of 450 msec as a risk factor for TdP (1). However, the low prevalence of TdP precludes using QTc prolongation alone to determine the risk of developing this condition (4). Arrhythmias are more likely to occur if drug-induced QTc prolongation co-occurs with other risk factors for QT prolongation, such as the presence of con-genital long QT syndromes, heart failure, bradycardia, electrolyte imbalances (hypokalemia, hypomagnesae-
mia, hypocalcaemia, hypophosphatemia), female sex, ad-vanced age, hepatic impairment, slow metabolization of methadone, concomitant use of a QTc-prolonging drug, cytochrome P-450 inhibitors such as selective serotonin reuptake inhibitors, antiretroviral medications and anti-psychotic medications (5, 6). Justo and colleagues found that the most prevalent risk factors for QTc prolongation were high-dose methadone (mean methadone dose was 231 ± 201 mg/day), drugs such as fluconazole and fluvox-amine that increase serum methadone levels, HIV infec-tion, hypokalemia, female sex, liver cirrhosis, and cardio-vascular disease (7).
2. ObjectivesThe aim of this study was to examine changes in the QTc duration before and after being on stable methadone treatment in veterans with heroin dependence and to as-sess QTc with risk factors such as methadone dosage, age, hypokalemia, hypocalcaemia, hypomagnesaemia, hypo-
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phosphatemia, systolic congestive heart failure, hepatic cirrhosis, antidepressant medication use, antipsychotic medication use, other QTc prolonging medications and gender, both independently and as a group, in a veteran patient population on a stable dose of methadone for opiate dependence (5-8). The relationship between the above risk factors as a group and the change in the mean QTc post-methadone was also analyzed. Differences in the clinical risk factors for veterans with a QTc change ≥ 24 msec were compared to those with a QTc change < 24 msec after being on methadone for an average of 8.72 ± 4.50 years.
3. Patiants and Methods
3.1. ParticipantsThe McGuire VAMC Opioid Agonist Treatment program provides integrated services to veterans with opiate dependence. At the time of the study, 47 male and 2 fe-male veterans were receiving methadone maintenance treatment. All of the 49 veterans meet DSM-IV criteria for heroin dependence (9). In this clinic, methadone liquid is administered at different dosages based on the veteran’s needs. At every methadone visit, an observed urine drug screen is performed. Initially, the veterans come into the methadone clinic daily for at least 90 days to pick up their daily dose of methadone. For every 90 negative urine drug screens, the veteran will get one extra take home dose of methadone. On average, veterans receive a 14-day supply of methadone at each visit, which translates to 1260 negative consecutive drug screens. For a positive urine drug screen, the veteran will lose methadone take home privileges. 3 positive urine drug screens usually re-sult in termination from the clinic. Comprehensive meta-bolic profiles and electrocardiograms were collected on admission to the program and yearly thereafter. Veterans with severe cardiopulmonary and liver disease were ex-cluded from methadone maintenance treatment.
3.2. ProceduresThe McGuire Veterans Hospital Institutional Review Board (IRB) approved our retrospective study. The study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki. Opiate dependence was defined using the DSM-IV criteria (9). All veterans enrolled in the methadone maintenance treatment program undergo routine laboratory analyses. From retrospective chart re-view, the most recent clinical data available after being on methadone was collected on all 49 veterans enrolled in the methadone maintenance program at the time of the study. Clinical data included 12-lead electrocardiograms and risk factors for QTc prolongation such hypokalemia, hypocalcaemia, hypomagnesaemia, hypophosphatemia, methadone dose, age, gender, systolic congestive heart failure, hepatic cirrhosis, antidepressant medication use, 
antipsychotic medication use, and the use of other QTc prolonging medications such as levofloxacin, atazana-vir/ritonavir, efavirenz, diltiazem, ciprofloxacin, trime-thoprim-sulfamethoxazole, azithromycin and vardenafil. Additional clinical data collected included full time em-ployment status, race, substance use disorder comorbid-ity, psychiatric disorder comorbidity and body mass in-dex. Electrocardiogram data prior to starting methadone was also collected on all 49 veterans.
3.3. Clinical VariablesThe QTc prior to initiating methadone treatment and the most up-to-date risk factors for QTc prolongation were correlated with the most recent QTc once the vet-eran had been on a stable dose of methadone. The QT interval was corrected for the heart rate using Bazett’s formula, QTc = QT√RR (10). Hypokalemia was defined as a potassium level of less than 3.5 mEq/L; hypocalcae-mia was defined as a calcium level of less than 8.5 mg/dL; hypomagnesaemia was defined as a magnesium level of less than 1.5 mg/dL; and hypophosphatemia was defined as a phosphorous level of less than 2.5 mg/dL. Systolic congestive heart failure was defined as hav-ing an ejection fraction less than 45%. Hepatic cirrhosis was defined as having ultrasound imaging or a liver biopsy showing hepatic fibrosis as well as documenta-tion confirming the diagnosis of cirrhosis. Other QTc prolonging medications included levofloxacin, ata-zanavir/ritonavir, efavirenz, diltiazem, ciprofloxacin, trimethoprim-sulfamethoxazole, azithromycin and vardenafil. All statistical analyses were calculated us-ing IBM SPSS software (11). QTc was correlated with risk factors as a dichotomous variable at 450 msec and as a continuous variable. The P-Value was set at ≤ 0.05. Con-tinuous variables (methadone dosage and age) were in-dependently correlated with a dichotomized QTc using a Point bi-serial correlation and a continuous QTc using a Pearson correlation. Ordinal variables (hypophospha-temia, hypocalcaemia, hypokalemia, hypomagnesae-mia, systolic congestive heart failure, liver cirrhosis) were independently correlated with a dichotomous and continuous QTc through Kendall’s tau correlations. Dichotomous variables (gender, antidepressant use, antipsychotic use, other QTc prolonging medications) were correlated with a dichotomized QTc based on the Phi Coefficient and the continuous QTc based on a Pear-son’s correlation. Multivariate ANOVA was performed to correlate the clinical risk factors (phosphate, calcium, potassium, magnesium, systolic heart disease, hepatic cirrhosis, methadone dose, age, gender, use of antide-pressant, use of antipsychotic medication, use of other QTc prolonging medications) as a group with the QTc as well as with the mean change in the QTc after 8.72 ± 4.50 years of Methadone Maintenance Treatment. A chi square and independent t-test was performed to analyze the difference in the clinical risk factors (phosphate, cal-
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cium, potassium, magnesium, systolic heart disease, hepatic cirrhosis, gender, use of antidepressant, use of antipsychotic medication, use of other QTc prolonging medications, methadone dose, age) between those vet-erans with a QTc change ≥ 24 msec and those with a QTc change < 24 msec after being on methadone for 8.72 ± 4.50 years. A change in the QTc of ≥ 24 msec was used to separate the veterans into two separate groups because the mean change in the QTc after being on a stable dose of methadone for all veterans was 24 msec.
4. ResultsAll the 49 veterans were receiving methadone mainte-nance for heroin dependence (Table 1). The mean QTc (± SD) prior to initiating methadone treatment was 426 ± 34 msec. The most recent EKG had been obtained after hav-ing been on a stable dose methadone for an average (± SD) of 8.72 ± 4.50 years. The mean QTc (± SD) after being on methadone for 8.72 ± 4.50 years was 450 ± 35 msec.
Table 1.  Sociodemographic Characteristics of the Sample (n = 49)   a
Variable Frequency
Age, y 56.96 ± 6.48
Body Mass Index, Kg/m2 29.63 ± 6.61
GenderMale 47 (96)Female 2 (4)
Race/EthnicityCaucasian 11 (22)African American 38 (78)
Full Time Employment 17 (35)
Substance Use Disorder ComorbidityNone 5 (10)Alcohol 2 (4)Cocaine 14 (29)Nicotine 8 (16)Marijuana 2 (4)Multiple 18 (37)
Psychiatric Disorder ComorbidityPost-Traumatic Stress Disorder 18 (37)Major Depressive Disorder 3 (6)Depressive Disorder Not Otherwise Specified 7 (14)Attention Deficit Hyperactivity Disorder 1 (2)Substance-Induced Mood Disorder 3 (6)Multiple Diagnosis (≥ 2) 4 (8)a Data are presented as No. (%) or Mean ± SD.
4.1. Overall Effect of Methadone on the QTcA paired t-test showed that the mean increase in the QTc (24 msec) after being on methadone treatment for an av-erage of 8.72 ± 4.50 years was statistically significant (t = -4.62, df = 46, P < 0.01).
4.2. Prevalence of Risk Factors for QTc Prolongation 
and TdPMethadone Dose: The mean dose of methadone (± SD) prescribed was 78.20 ± 25.30 mg/day. QTc prolongation: On admission to the methadone maintenance treat-ment program, 40 veterans (82 %) displayed a QTc less than or equal to 450 msec, while 9 (18%) displayed a QTc greater than 450 msec. 4 veterans had a QTc between 450 to 475 msec, 3 veterans had a QTc between 475 msec and 500 msec, 1 veteran had a QTc between 500 msec and 525 msec, 1 veteran had a QTc between 525 msec and 550 msec. The average heart rate (± SD) was 72.00 ± 11.81 bpm. After being on methadone for an average of 8.72 ± 4.50 years, 26 (53%) veterans displayed a QTc of less than or equal to 450 msec, while 23 (47%) exhibited a QTc greater than 450 msec. 19 veterans had a QTc between 450 msec and 475 msec; 2 veterans had a QTc between 475 msec and 500 msec; 1 veteran had a QTc between 500 msec and 525 msec; 3 veterans had a QTc between 525 msec and 550 msec. The average heart rate (± SD) was 70.00 ± 12.89 bpm.TdP: Despite the fact that 47% of the participants pre-sented a QTc greater than 450 msec post methadone, none of the participants experienced any arrhythmias. Psychotropic Medications: 24 (49%) were on an antide-pressant medication; and 4 (8%) were on an antipsychotic medication.Electrolytes: 6 (12%) veterans were hypokalemic, 11 (22.45%) had hypocalcaemia while 10 (20%) had hypomag-nesaemia, and 1 (2%) had hypophosphatemia. Co-morbid physical disorders: 13 (26.53%) had cirrhosis, 2 (4.08%) had systolic congestive heart failure.
4.3. Effect of Risk Factors on the QTc After Initiating 
MethadonePoint-biserial correlations revealed no significant asso-ciation between the dichotomized QTc and methadone dosage (r = 0.19, P = 0.19) or age (r = 0.17, P = 0.24). Pear-son’s correlation revealed no significant correlation between the continuous QTc and methadone dosage (r = 0.18, P = 0.22) or age (r = 0.17, P = 0.24). Kendall’s Tau correlations did not indicate any significant association between dichotomized QTc and potassium (τ = -0.18, P = 0.20), magnesium (τ = -0.11, P = 0.48), phosphate (τ = -0.15, P = 0.33), systolic heart failure (τ = 0.225, P = 0.06) or cirrhosis (τ = -0.20, P = 0.09). However, Kendall’s Tau correlations did indicate a significant association between dichotomized QTc and calcium (τ = -0.35, P = 0.02). Similarly, Kendall’s Tau correlations did not show any significant correlations between continuous 
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Table 2.  Case Report Risk Factors for QTc Interval Prolongation and Torsade de Pointes (TdP) in Descending Order of the Change in the QTc on a Stable Dose of Methadone
Case # Current risk Factors Other Than 
Methadone
Change in 
QTc, msec
Pre methadone 
QTc, msec
On a stable dose of 
methadone QTc, msec
Methadone daily 
dose, mg
Age, y
#38 hypo-mg++ 122 398 520 85 56
#21 none 108 430 538 90 61
#23 quetiapine 96 453 549 120 61
#3 venlafaxine 79 377 456 100 41
#32 none 75 401 476 85 52
#41 bradycardia, citalopram 68 387 455 120 60
#31 hypo-K+, hypo-ca++, trazodone 60 412 472 90 59
#9 trazodone 58 390 448 65 55
#28 sertraline, trazodone 55 403 458 55 56
#7 paroxetine 55 402 457 100 59
#19 hypo-ca++, azithromycin 51 401 452 110 59
#48 bradycardia, diltiazem 51 400 451 45 64
#40 none 45 399 434 80 53
#45 hypo-mg++, hypo-ca++, amitryptiline 41 433 474 60 55
#36 hepatic cirrhosis, hypo-mg++, azithromycin, ciprofloxacin, trimethoprim sulfamethoxazole, trazadone
40 410 450 85 51
#44 female, hypo-K+, bradycardia, venlafaxine 36 394 430 70 50
#12 risperidone, levofloxacin, trazodone 35 436 471 175 55
#20 none 28 424 452 70 61
#43 hepatic cirrhosis 28 422 450 65 64
#2 hepatic cirrhosis, hypo-Mg++, trazodone 28 418 446 85 60
#27 hepatic cirrhosis 28 394 422 100 61
#30 hypo-Ca++ 24 400 424 80 59
#17 hepatic cirrhosis 24 396 420 100 62
#29 none 23 382 405 95 39
#46 hypo-po43-, hypo-ca++, hepatic cirrhosis, azithromycin, trazodone 21 439 460 50 53
#35 hepatic cirrhosis, hypo-mg++, hypo-ca++, sertraline 20 431 451 100 62
#33 levofloxacin, hypo-ca++ 19 479 498 55 63
#11 hypo-ca++, systolic heart failure 15 451 466 70 75
#5 hypo-k+, hypo-mg++, bradycardia, sertraline 14 431 445 80 61
#14 hypo-ca++, amitriptyline 14 413 427 55 63
#26 bradycardia 12 398 410 70 59
#18 atazanavir, ritonavir 8 424 432 60 56
#13 hepatic cirrhosis, quetiapine, sertraline 6 436 442 100 59
#6 hypo-k+ 4 470 474 75 58
#37 bradycardia 1 398 399 70 54
#22 hepatic cirrhosis, systolic heart failure, hypo-k+, hypo-mg++, hypo-ca++, trazodone 0 536 536 60 57
#42 hypo-k+, trazodone 0 459 459 90 51
#25 female 0 439 439 55 50
#8 hepatic cirrhosis, mirtazapine 0 434 434 55 54
#4 bradycardia 0 428 428 80 64
#34 sertraline, hepatic cirrhosis 0 416 416 45 61
#49 hypo-Mg++ 0 403 403 50 55
#39 vardenifil -3 445 442 60 60
#16 none -13 409 396 90 55
#47 efavrienz, trazodone -15 416 401 100 57
#15 hepatic cirrhosis, hypo-Mg++, trazodone -22 484 462 70 57
#24 mirtazapine, bradycardia -29 438 409 30 55
#10 none -56 499 443 90 37
#1 hypo-mg++, hypo-ca+, quetiapine, nortriptyline -64 519 455 40 62
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QTc and potassium (τ = 0.11, P = 0.35), magnesium (τ = 0.06, P = 0.62), phosphate (τ = -0.14, P = 0.25), systolic heart failure (τ = 0.22, P = 0.07) or cirrhosis (τ = -0.08, P = 0.52). However, Kendall’s Tau correlations did show a significant correlation between the continuous QTc and calcium (τ = -0.25, P = 0.05). The phi coefficient did not show any significant association between the dichoto-mized QTc and gender (φ = -0.19, P = 0.17), antidepres-sant use (φ = 0.14, P = 0.32), antipsychotic use (φ = 0.17, P = 0.24), and other QTc prolonging medications (φ = 0.09, P = 0.53). The Pearson’s correlation did not show any significant correlation between the continuous QTc and gender (r = -0.09, P = 0.53), antidepressant use (r = -0.06, P = 0.69), antipsychotic use (r = 0.26, P = 0.07) and other QTc prolonging medications (r = -0.02, P = 0.87).
4.4. Effect of the Risk Factors as a Group on the QTc 
After Initiating MethadoneMultivariate ANOVA did not show a significant corre-lation between the risk factors as a group (methadone dosage, age, hypokalemia, hypocalcaemia, hypomagne-saemia, hypophosphatemia, systolic congestive heart failure, hepatic cirrhosis, antidepressant medication use, antipsychotic medication use, other QTc prolonging medications, and gender) and the continuous QTc (F = 1.18, df = 12, P = 0.34).
4.5. Effect of the Risk Factors as a Group on the 
Change in the QTc After Initiating MethadoneMultivariate ANOVA did not show a significant corre-lation between the risk factors as a group (methadone dosage, age, hypokalemia, hypocalcaemia, hypomagne-saemia, hypophosphatemia, systolic congestive heart failure, hepatic cirrhosis, antidepressant medication use, antipsychotic medication use, other QTc prolonging medications, gender) and the mean change in the QTc (F = 1.78, df = 12, P = 0.10).
4.6. Difference in the Clinical Risk Factors Between 
Veterans With a Change of QTc ≥ 24 Msec and 
Those With a QTc < 24 MsecA chi-square did not show any significant differences in antidepressant use (χ2 = 0.18, df = 1, P = 0.67), antipsy-chotic use (χ2 = 0.02, df = 1, P = 0.90), other QTc prolong-ing medication (χ2 = 0.05, df = 1, P = 0.84), gender (χ2 = 0.01, df = 1, P = 0.93), hypocalcaemia (χ2 = 0.91, df = 1, P = 0.34), hypomagnesaemia (χ2 = 0.28, df = 1, P = 0.60), hy-pophosphatemia (χ2 = 1.18, df = 1, P = 0.28), hypokalemia (χ2 = 1.20, df = 2, P = 0.55) systolic congestive heart failure (χ2 = 1.84, df = 1 P = 0.18) and hepatic cirrhosis (χ2 = 0.50, df = 1, P = 0.48) between the 2 groups of veterans. An in-dependent t-test did not show a significant difference in age between the 2 groups of veterans (t = -0.17, df = 47, P = 0.86). The mean dose of methadone prescribed for veter-ans (88.48 ± 27.20 mg) with a change in QTc ≥ 24 msec was 
significantly higher than the mean dose of methadone (68.96 ± 19.84 mg) prescribed for veterans with a change in QTc < 24 msec (t = 2.82, df = 45 P = 0.01).
5. DiscussionMales are highly over-represented in our veterans there-fore our results should not be extrapolated to the general population.
5.1. Methadone-Associated QTc ProlongationAfter being on a stable dose of methadone for 8.72 ± 4.50 years there was a statistically significant increase in the QTc (mean 24 msec). The modification of QTc during methadone maintenance does not seem to be progres-sive throughout the years. Our findings are consistent with those of Wedham and colleagues, who observed an increase in the QTc from baseline to 4 weeks, 8 weeks and 16 weeks in 23% of patients receiving methadone main-tenance treatment with a normal QTc at baseline (12). In the present study, there was no significant association between QTc prolongation and the methadone dose simi-lar to the findings of Roy and colleagues who found no significant correlation between the mean QTc of 420.9 ± 21.2 msec, and the mean daily dose of methadone, which was 80.4 ± 27.7 mg, in their patients receiving methadone maintenance treatment (13). In our study however, there was a significant difference in the methadone dosage be-tween the groups with ≥ 24 msec increase in QTc and < 24 msec increase (88.48 ± 27.20 mg versus 68.96 ± 19.84 mg). But the relationship between methadone dosage, methadone blood level and QTc prolongation is unclear. A study by Peles and colleagues found that the dose of methadone and serum methadone levels did not corre-late with QTc (14).
5.2. Age and QTc ProlongationIn general, the aging process is an independent risk factor for QTc prolongation and for the development of arrhythmias. The QTc may increase with age secondary to fibrosis and amyloidosis of the myocardium as well as cardiac hypertrophy and aortic impedance (15). How-ever, similar to the present work, other studies have pro-duced conflicting results regarding the relationship be-tween age and the QTc. For example, Merri and colleagues quantified electrographic ventricular repolarization and found no relationship between age and the QT interval (16). Due to the narrow age range of our veteran popula-tion (56.96 ± 6.48 years), it was highly unlikely that we would find a significant correlation between age and the QTc. In addition, we did not explore the impact of other cardiovascular factors such as smoking status, which could affect the relationship between age and the QTc.
5.3. Gender and QTc ProlongationFemale gender appears be an independent risk factor 
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for QTc prolongation. Men exhibit shorter resting QTcs and are therefore less likely to develop TdP secondary to the influence of sex hormones on ventricular repolariza-tion (17). A review of FDA databases performed by Ebert and colleagues found that a higher percentage of women compared to men developed TdP in response to a variety of drugs that share an ability to block potassium currents (18). Due to the low prevalence of females (n = 2) in our study population, it is highly unlikely that we would find a statistically significant difference between gender and the QTc.
5.4. Electrolytes and QTC ProlongationFluctuations in electrolytes can prolong the QTc. Hypo-kalemia, hypomagnesaemia, hypophosphatemia and hy-pocalcaemia have been associated with increased QTc (19-21). The lack of a significant negative correlation between hypokalemia, hypomagnesaemia or hypophosphatemia and the QTc observed in our study population can most likely be attributed to the lack of severe electrolyte ab-normalities. Golzari and colleagues examined the effects of hypokalemia, hypocalcaemia and hypomagnesaemia on the QTc and observed that the prevalence of abnormal QTcs varied based on the applied criteria, ranging from 25.2%, when using the most lenient criteria (QTc ≥ 450 msec.), to 3.5%, when the most restrictive criteria were applied (QTc ≥ 500 msec.) (6). Although the QTc was di-chotomized at 450 msec in our study, there was no signif-icant negative correlation found between hypokalemia, hypomagnesaemia and hypophosphatemia. However, in our study there was a significant negative association between calcium and the dichotomized and continuous QTc. Hypocalcaemia has been shown to prolong the QT interval and that calcium replacement decreases the QT interval (22).
5.5. Drug Interactions and QTC ProlongationMethadone is metabolized hepatically by N-demeth-ylation via various cytochrome P450 isoforms (23). Therefore, administration of cytochrome P450 inhibi-tors, such as antidepressants and antipsychotics, will decrease the metabolism of methadone and enhance its effects, resulting in QTc prolongation (23). In addition, independent of cytochrome P450 inhibition, certain SS-RIs and antipsychotics can prolong the QTc (24, 25). Se-lective serotonin reuptake inhibitors (SSRIs), as a class, are associated with QTc prolongation, with citalopram being the most likely to be associated with this phenom-enon, especially at doses greater than 40 mg/day (23). In the present study, the lack of a significant correlation between antidepressants and the QTc can be attributed to the therapeutic doses of antidepressants used. Addi-tionally, tricyclic anti-depressants (TCA’s) have a higher rate of QTc prolongation compared to other anti-depres-sants classes (26). In our study, only 3 of the 24 veterans on an anti-depressant were being prescribed a TCA. An-
tipsychotics can also prolong the QTc; however, this ef-fect differs based on the particular type of antipsychot-ic studied (25). Through analysis of 1,017 patients with schizophrenia, Ozeki and colleagues found that chlor-promazine, intravenous haldol and sultropride were associated with an increased QTc at therapeutic doses, whereas olanzapine, quetiapine, risperidone and zot-epine were not associated with an increased QTc (25). In their study, the effect of ziprasidone on the QTc was not analyzed, which is notable because among the atypical antipsychotics, ziprasidone appears to be most likely to prolong the QTc (27). In the present study, the lack of a significant correlation between antipsychotics and the QTc can be attributed to the fact that none of the veter-ans was on chlorpromazine, intravenous haldol, sultro-pride or ziprasidone.
5.6. Medical Comorbidities and QTc ProlongationProlongation of the QTc is observed in a number of heart conditions, especially in association with struc-tural heart defects such as heart failure (28). The absence of a significant association between systolic congestive heart failure and the QTc observed in our veteran popu-lation is most likely due to the low prevalence (4.08%) of veterans with systolic heart failure receiving MMT and the dynamic nature of the QT interval under heart failure. Hepatic disease, in particular liver cirrhosis, has been documented as a risk factor for QTc prolonga-tion (29). QTc prolongation tends to be more severe in patients with alcoholic cirrhosis or Child-Pugh Class C cirrhosis (29). The absence of a significant association between cirrhosis and QTc in our study is due to none of the veterans having cirrhosis severe enough to be classi-fied as Child-Pugh Class C.The low incidence (0%) of cardiac arrhythmias observed in this study could be due to the fact that we were inter-ested in and included only veterans who stayed in the methadone program for many years, the moderate dose of methadone prescribed (78.20 ± 25.30 versus 99 ± 49 mg/day) and the relatively low prevalence of electrolyte abnormalities and medical comorbidities (30). Thus vet-erans who were originally enrolled in the methadone maintenance program but left the program in the early stages of their treatment due to any reason are not in-cluded. Therefore including only veterans with long-term methadone treatment may have excluded those veterans with more severe QT prolongation or who may have left the program due to arrhythmias, early on. But epidemio-logical data do not support a correlation between metha-done and substantial TdP mortality (31). We found that af-ter being on methadone for an average of 8.72 ± 4.50 years, the QTc increased significantly by an average of 24 msec. The change in the QTc does not appear to be progressive throughout the years. The higher dose of methadone was the only clinical risk factor that significantly differenti-ated those veterans with a QTc change ≥ 24 msec versus 
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those veterans with a QTc change < 24 msec. The absence of a significant correlation observed between the risk fac-tors except calcium and the QTc can be attributed to the low power of the study (n = 49) as well as the lack of sever-ity and complexity among the assessed co-morbidities. Thus our data supports that methadone dose is a mate-rial factor in QTc increase but does not support the dose being a risk factor both independently or in combination with other risk factors for inducing TdP or polymorphic ventricular arrhythmias (PVA). Concern of increasing ar-rhythmias in patients on methadone has come mostly from case-reports, while many epidemiological studies have not shown a significant increase in arrhythmias (31). A review by the Cochrane group found no evidence to support the use of routine EKG monitoring for prevent-ing arrhythmias in methadone maintained patients (32). The QTc thresholds for ventricular arrhythmias are not specific and a significant proportion of cardiac events oc-cur at QTc values lower than 450 msec. During long-term methadone maintenance treatment, there was slight in-crease in the QTc interval but we did not find evidence of increased cardiac toxicity as a reason for treatment ter-mination. A limitation of the study is the non-inclusion of veterans who were originally enrolled in the metha-done maintenance program but left the program before the initiation of the study. Other limitations include the small cohort size.
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